887282-93-1

Usage

Uses

Used in Pharmaceutical Industry:
(6-methyl-2-(p-tolyl)imidazo[1,2-a]pyridin-3-yl)methanol is used as a potential therapeutic agent for various medical conditions due to its possible biological activities. (6-methyl-2-(p-tolyl)imidazo[1,2-a]pyridin-3-yl)methanol's anti-inflammatory, antibacterial, antiviral, and anticancer properties make it a promising candidate for the development of new drugs to treat a range of diseases.
Used in Drug Delivery Systems:
In the field of drug delivery, (6-methyl-2-(p-tolyl)imidazo[1,2-a]pyridin-3-yl)methanol may be utilized as a component in the design of novel drug delivery systems. Its unique chemical structure could be exploited to improve the delivery, bioavailability, and therapeutic outcomes of associated pharmaceutical agents, particularly in the treatment of cancer and other diseases where its biological activities could be beneficial.
Used in Chemical Research:
(6-methyl-2-(p-tolyl)imidazo[1,2-a]pyridin-3-yl)methanol is also used as a subject of study in chemical research. Its synthesis, structural analysis, and investigation of its potential biological activities can contribute to the advancement of knowledge in medicinal chemistry and the development of new therapeutic strategies.

Upstream product

• 193979-41-8 ethyl 6-methyl-2-(4-methyl-phenyl)imidazo[1,2-a]pyridine-3-carboxylate 
• 50-00-0 formaldehyd 
• 224633-83-4 6-methyl-2-p-tolyl-imidazo[1,2-a]pyridin-4-ium bromide 
• 88965-00-8 6-methyl-2-(4-methyl-phenyl)-imidazo[1,2-a]pyridine 
• 107-21-1 ethylene glycol 
• 619-41-0 4-(bromoacetyl)toluene 
• 400777-11-9 6-methyl-2-(p-tolyl)imidazo[1,2-a]pyridine-3-carbaldehyde 
• 140166-68-3 ethyl 2-bromo-3-(4-methylphenyl)-3-oxopropanoate 
• 1603-41-4 (5-methyl-pyridin-2-yl)amine 

Downstream Products

• 1197849-51-6 3-(chloromethyl)-6-methyl-2-p-tolyl-imidazo[1,2-a]pyridine hydrochloride 
• 1197846-01-7 3-((1H-imidazol-1-yl)methyl)-6-methyl-2-p-tolylimidazo[1,2-a]pyridine 
• 1197847-91-8 N-((6-methyl-2-p-tolyl-imidazo[1,2-a]pyridin-3-yl)methyl)pyrimidin-2-amine 
• 1197847-21-4 1-methyl-3-((6-methyl-2-p-tolyl-imidazo[1,2-a]pyridin-3-yl)methyl)imidazolidin-2-one 
• 1197847-20-3 1,2-dihydro-3-methyl-1-((6-methyl-2-p-tolyl-imidazo[1,2-a]pyridin-3-yl)methyl)pyrazol-5-one 
• 106961-33-5 dimethyl-(6-methyl-2-p-tolylimidazo[1,2-a]pyridin-3-ylmethyl)-amine 

Relevant academic research and scientific papers

KIO4-mediated Selective Hydroxymethylation/Methylenation of Imidazo-Heteroarenes: A Greener Approach

Herein, we report a KIO4-mediated, sustainable and chemoselective approach for the one-pot C(sp2)?H bond hydroxymethylation or methylenation of imidazo-heteroarenes with formaldehyde, generated in situ via the oxidative cleavage of ethylene glycol or glycerol (renewable reagents) through the Malaprade reaction. In the presence of ethylene glycol, a series of 3-hydroxymethyl-imidazo-heteroarenes was obtained in good to excellent yields. These compounds are important intermediates to access pharmaceutical drugs, e.g., Zolpidem. Furthermore, by using glycerol, bis(imidazo[1,2-a]pyridin-3-yl)methane derivatives were selectively obtained in good to excellent yields.

IMIDAZO[1,2-a]PYRIDINE COMPOUNDS

Imidazo[1,2-a]pyridines are disclosed. Compounds of the invention are useful therapeutic agents and their inclusion in pharmaceutical formulations and use in methods of treatment are disclosed.

IMIDAZO[1,2-A]PYRIDINE COMPOUNDS, COMPOSITIONS, USES AND METHODS RELATED THERETO

The present invention relates to novel imidazo[1,2- a]pyridine compounds of general formula (I) as well as pharmaceutically acceptable salts thereof; wherein R1, R2, R3 and R4 are as defined in the claims. The c

Synthesis and binding affinity of 2-phenylimidazo[1,2-α]pyridine derivatives for both central and peripheral benzodiazepine receptors. A new series of high-affinity and selective ligands for the peripheral type

A number of 6-substituted or 6,8-disubstituted alkyl 2- phenylimidazo[1,2-a]pyridine-3-carboxylates 5a-h,-acetates 5i-s, 6a-g, and - propionates 5t, 6h and of N,N-dialkyl-2-phenylimidazo[1,2-α]pyridlne-3- carboxamides 7a-d, -aceramides 7e-t or -propionamide 7u were prepared following new synthetic methods, and their affinities for both the central (CBR) and the peripheral (PBR) benzodiazepine receptors evaluated. The compounds of the ester series displayed low affinity for both receptor types. Conversely, most of N,N-dialkyl(2-phenylimidazo[1,2-a]pyridin-3-yl)acetamides 7e-t proved to possess high affinity and selectivity for CBR or PBR depending on the nature of substituents at C(6)- and/or C(8) on the heterocyclic ring system. In particular, the 6-substituted compounds 7f-n displayed ratios of IC50 values (IC50(CBR)/IC50(PBR)) ranging from 0.32 (7m) to 232 (7k), while the 6,8-disubstituted compounds 7o-t were more than 1000-fold more selective for PBR versus CBR. Compounds 7f,m were examined in several different benzodiazepine receptor subtypes. Expression of specific GABA(A) receptor subunit assemblies in Xenopus oocytes was utilized to evaluate functionally both the efficacy and potency of the positive modulation of GABA-evoked C1+ currents by 7f and 7m in comparison with Zolpidem. The rank order of potencies of these drugs was 7f (EC50 = 3.2 x 10-8 M) > Zolpidem (EC50 = 3.6 x 10-8 M) > 7m (EC50 = 2.2 x 10-7 M). The actions of these compounds were also tested on α2β2γ2(s) receptors. However, the EC50 of these compounds was increased, compared to α1β2γ2(s) receptors, by 30-, 4-, and 5-fold for 7m, 7f, and Zolpidem, respectively. Finally, these compounds were almost completely devoid of activity at receptors containing the α5 subunit.